$PTGX
Protagonist Therapeutics, Inc Stock $ptgx

$ptgx Overview Financials Valuation SEC Filings Company Website

2017 Q4 Form 10-Q Financial Statement

#000137712117000007 Filed on November 07, 2017

Income Statement

Concept	2017 Q4	2017 Q3	2016 Q4
Revenue	$11.28M	$8.781M	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.070M	$2.590M	$2.570M
YoY Change	19.46%	63.92%	217.28%
% of Gross Profit
Research & Development	$11.72M	$11.17M	$8.820M
YoY Change	32.88%	100.83%	110.5%
% of Gross Profit
Depreciation & Amortization	$120.0K	$110.0K	$80.00K
YoY Change	50.0%	37.5%	-11.11%
% of Gross Profit
Operating Expenses	$14.80M	$13.76M	$11.40M
YoY Change	29.82%	92.79%	128.0%
Operating Profit		-$4.980M	-$11.40M
YoY Change		-30.23%	127.89%
Interest Expense	$460.0K	$160.0K	$150.0K
YoY Change	206.67%	220.0%	-130.61%
% of Operating Profit
Other Income/Expense, Net	$0.00	$0.00	$0.00
YoY Change
Pretax Income	-$3.050M	-$4.830M	-$11.25M
YoY Change	-72.89%	-31.78%	104.92%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$3.050M	-$4.825M	-$11.25M
YoY Change	-72.88%	-31.89%	104.77%
Net Earnings / Revenue	-27.04%	-54.95%
Basic Earnings Per Share
Diluted Earnings Per Share	-$150.8K	-$285.6K	-$767.4K
COMMON SHARES
Basic Shares Outstanding	20.48M shares	16.90M shares	16.71M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q4	2017 Q3	2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$144.0M	$93.60M	$77.60M
YoY Change	85.57%	-4.97%	552.1%
Cash & Equivalents	$106.5M	$50.40M	$21.08M
Short-Term Investments	$38.00M	$43.20M	$56.50M
Other Short-Term Assets	$3.800M	$2.700M	$906.0K
YoY Change	319.43%	50.0%	197.05%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$150.9M	$97.70M	$83.24M
YoY Change	81.27%	-4.44%	485.98%
LONG-TERM ASSETS
Property, Plant & Equipment	$900.0K	$945.0K	$562.0K
YoY Change	60.14%	67.55%	-7.72%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$11.50M	$11.30M	$10.20M
YoY Change	12.75%
Other Assets	$500.0K	$0.00	$34.00K
YoY Change	1370.59%	-100.0%	13.33%
Total Long-Term Assets	$12.80M	$12.71M	$10.75M
YoY Change	19.11%	2025.59%	1581.69%
TOTAL ASSETS
Total Short-Term Assets	$150.9M	$97.70M	$83.24M
Total Long-Term Assets	$12.80M	$12.71M	$10.75M
Total Assets	$163.7M	$110.4M	$93.99M
YoY Change	74.17%	7.36%	533.14%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.300M	$2.267M	$1.163M
YoY Change	11.78%	-2.91%	-6.74%
Accrued Expenses	$9.400M	$8.241M	$5.272M
YoY Change	78.3%	173.42%	180.57%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$42.60M	$52.25M	$6.435M
YoY Change	562.0%	876.76%	105.85%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$500.0K	$300.0K
YoY Change
Total Long-Term Liabilities	$500.0K	$300.0K	$0.00
YoY Change			-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$42.60M	$52.25M	$6.435M
Total Long-Term Liabilities	$500.0K	$300.0K	$0.00
Total Liabilities	$43.10M	$52.58M	$6.435M
YoY Change	569.77%	882.97%	22.59%
SHAREHOLDERS EQUITY
Retained Earnings		-$98.50M	-$64.59M
YoY Change		84.64%	135.6%
Common Stock		$156.2M	$152.4M
YoY Change		3.56%	129046.61%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$120.6M	$57.84M	$87.56M
YoY Change
Total Liabilities & Shareholders Equity	$163.7M	$110.4M	$93.99M
YoY Change	74.17%	7.36%	533.14%

Cashflow Statement

Concept	2017 Q4	2017 Q3	2016 Q4
OPERATING ACTIVITIES
Net Income	-$3.050M	-$4.825M	-$11.25M
YoY Change	-72.88%	-31.89%	104.77%
Depreciation, Depletion And Amortization	$120.0K	$110.0K	$80.00K
YoY Change	50.0%	37.5%	-11.11%
Cash From Operating Activities	-$14.15M	$40.70M	-$9.680M
YoY Change	46.18%	-683.09%	104.22%
INVESTING ACTIVITIES
Capital Expenditures	-$60.00K	-$190.0K	-$50.00K
YoY Change	20.0%	280.0%	-77.27%
Acquisitions
YoY Change
Other Investing Activities	$4.810M	-$580.0K	-$64.27M
YoY Change	-107.48%	-114.76%	716.65%
Cash From Investing Activities	$4.750M	-$770.0K	-$64.33M
YoY Change	-107.38%	-119.79%	696.16%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	65.06M	30.00K	-850.0K
YoY Change	-7754.12%	-99.96%
NET CHANGE
Cash From Operating Activities	-14.15M	40.70M	-9.680M
Cash From Investing Activities	4.750M	-770.0K	-64.33M
Cash From Financing Activities	65.06M	30.00K	-850.0K
Net Change In Cash	55.66M	39.96M	-74.86M
YoY Change	-174.35%	-51.38%	483.93%
FREE CASH FLOW
Cash From Operating Activities	-$14.15M	$40.70M	-$9.680M
Capital Expenditures	-$60.00K	-$190.0K	-$50.00K
Free Cash Flow	-$14.09M	$40.89M	-$9.630M
YoY Change	46.31%	-690.04%	113.05%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.01
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Document Period End Date DocumentPeriodEndDate	2017-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001377121
CY2017Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	20479663	shares
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	PROTAGONIST THERAPEUTICS, INC
	dei	Trading Symbol TradingSymbol	PTGX
	ptgx	Accretion Of Redeemable Convertible Preferred Stock AccretionOfRedeemableConvertiblePreferredStock	558000	USD
	ptgx	Accretion Of Redeemable Convertible Preferred Stock AccretionOfRedeemableConvertiblePreferredStock	0	USD
CY2016Q4	ptgx	Accrued Clinical And Research Related Expenses Current AccruedClinicalAndResearchRelatedExpensesCurrent	3617000	USD
CY2017Q3	ptgx	Accrued Clinical And Research Related Expenses Current AccruedClinicalAndResearchRelatedExpensesCurrent	5864000	USD
CY2016Q4	ptgx	Cash Equivalents And Available For Sale Securities Amortized Cost CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost	85241000	USD
CY2017Q3	ptgx	Cash Equivalents And Available For Sale Securities Amortized Cost CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost	102196000	USD
CY2016Q4	ptgx	Cash Equivalents And Available For Sale Securities Fair Value CashEquivalentsAndAvailableForSaleSecuritiesFairValue	85169000	USD
CY2017Q3	ptgx	Cash Equivalents And Available For Sale Securities Fair Value CashEquivalentsAndAvailableForSaleSecuritiesFairValue	102145000	USD
CY2016Q4	ptgx	Cash Equivalents And Available For Sale Securities Gross Unrealized Gain CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGain	2000	USD
CY2017Q3	ptgx	Cash Equivalents And Available For Sale Securities Gross Unrealized Gain CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGain	0	USD
CY2016Q4	ptgx	Cash Equivalents And Available For Sale Securities Gross Unrealized Loss CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLoss	74000	USD
CY2017Q3	ptgx	Cash Equivalents And Available For Sale Securities Gross Unrealized Loss CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLoss	51000	USD
CY2017Q3	ptgx	Contractwith Customer Asset Period Increase ContractwithCustomerAssetPeriodIncrease	520000	USD
	ptgx	Contractwith Customer Asset Period Increase ContractwithCustomerAssetPeriodIncrease	520000	USD
CY2017Q3	ptgx	Contractwith Customer Liability Period Increase ContractwithCustomerLiabilityPeriodIncrease	50000000	USD
	ptgx	Contractwith Customer Liability Period Increase ContractwithCustomerLiabilityPeriodIncrease	50132000	USD
CY2016Q3	ptgx	Fair Value Adjustment Of Tranche And Warrants FairValueAdjustmentOfTrancheAndWarrants	0	USD
	ptgx	Fair Value Adjustment Of Tranche And Warrants FairValueAdjustmentOfTrancheAndWarrants	4719000	USD
CY2017Q3	ptgx	Fair Value Adjustment Of Tranche And Warrants FairValueAdjustmentOfTrancheAndWarrants	0	USD
	ptgx	Fair Value Adjustment Of Tranche And Warrants FairValueAdjustmentOfTrancheAndWarrants	0	USD
	ptgx	Fair Value Adjustment Of Tranche Liability FairValueAdjustmentOfTrancheLiability	4194000	USD
	ptgx	Fair Value Adjustment Of Tranche Liability FairValueAdjustmentOfTrancheLiability	0	USD
	ptgx	Increase Decrease In Research And Development Tax Incentive Receivable IncreaseDecreaseInResearchAndDevelopmentTaxIncentiveReceivable	1229000	USD
	ptgx	Increase Decrease In Research And Development Tax Incentive Receivable IncreaseDecreaseInResearchAndDevelopmentTaxIncentiveReceivable	-1530000	USD
	ptgx	Reclassification Of Preferred Stock Warrant Liability To Equity ReclassificationOfPreferredStockWarrantLiabilityToEquity	1005000	USD
	ptgx	Reclassification Of Preferred Stock Warrant Liability To Equity ReclassificationOfPreferredStockWarrantLiabilityToEquity	0	USD
CY2016Q1	ptgx	Settlement Of Fair Value Of Redeemable Convertible Preferred Stock Liability SettlementOfFairValueOfRedeemableConvertiblePreferredStockLiability	5800000	USD
	ptgx	Settlement Of Fair Value Of Redeemable Convertible Preferred Stock Liability SettlementOfFairValueOfRedeemableConvertiblePreferredStockLiability	5837000	USD
	ptgx	Settlement Of Fair Value Of Redeemable Convertible Preferred Stock Liability SettlementOfFairValueOfRedeemableConvertiblePreferredStockLiability	0	USD
	ptgx	Stock Issuance Costs Incurred But Not Yet Paid StockIssuanceCostsIncurredButNotYetPaid	860000	USD
	ptgx	Stock Issuance Costs Incurred But Not Yet Paid StockIssuanceCostsIncurredButNotYetPaid	0	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1163000	USD
CY2017Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2267000	USD
CY2016Q2	ptgx	Remeasured Fair Value Of Warrants RemeasuredFairValueOfWarrants	1000000	USD
CY2016Q4	ptgx	Research And Development Tax Incentive Receivable ResearchAndDevelopmentTaxIncentiveReceivable	2241000	USD
CY2017Q3	ptgx	Research And Development Tax Incentive Receivable ResearchAndDevelopmentTaxIncentiveReceivable	885000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-82000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-497000	USD
CY2016Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	1420000	USD
CY2017Q3	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	1611000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5272000	USD
CY2017Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8241000	USD
CY2016Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	115000	USD
CY2017Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	709000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-245000	USD
CY2017Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	100000	USD
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	152393000	USD
CY2017Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	156234000	USD
CY2016Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	448000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	610000	USD
CY2017Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1207000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3052000	USD
CY2016Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1496156	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1496156	shares
CY2017Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2564354	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2564354	shares
CY2016Q4	us-gaap	Assets Assets	93990000	USD
CY2017Q3	us-gaap	Assets Assets	110415000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	83244000	USD
CY2017Q3	us-gaap	Assets Current AssetsCurrent	97704000	USD
CY2016Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	85169000	USD
CY2017Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	102146000	USD
CY2016Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	56515000	USD
CY2017Q3	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	43191000	USD
CY2016	us-gaap	Available For Sale Securities Gross Realized Gain Loss Net AvailableForSaleSecuritiesGrossRealizedGainLossNet	0	USD
	us-gaap	Available For Sale Securities Gross Realized Gain Loss Net AvailableForSaleSecuritiesGrossRealizedGainLossNet	0	USD
CY2016Q4	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	10150000	USD
CY2017Q3	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	11316000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	6000	USD
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	96024000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21084000	USD
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	50395000	USD
CY2015Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4065000	USD
CY2016Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	96034000	USD
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	21094000	USD
CY2017Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	50855000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	91969000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	29761000	USD
CY2016Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	18504000	USD
CY2017Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	47638000	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2017Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	90000000	shares
CY2017Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	90000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16722280	shares
CY2017Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16944103	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16722280	shares
CY2017Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16944103	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	0	USD
CY2017Q3	us-gaap	Common Stock Value CommonStockValue	0	USD
CY2016Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7008000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-25851000	USD
CY2017Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4728000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-33560000	USD
CY2016Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	0	USD
CY2017Q2	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	0	USD
CY2017Q3	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	520000	USD
CY2016Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	0	USD
CY2017Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	0	USD
CY2017Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	41739000	USD
CY2017Q3	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-8261000	USD
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-8393000	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	66904000	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
CY2016Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	0	USD
CY2017Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	332000	USD
CY2016Q4	us-gaap	Deferred Revenue DeferredRevenue	0	USD
CY2017Q3	us-gaap	Deferred Revenue DeferredRevenue	41739000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	242000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	289000	USD
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.87
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-8.62
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.29
	us-gaap	Investment Income Interest InvestmentIncomeInterest	93000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	105000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	177000	USD
CY2017Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	11700000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y7M6D
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	525000	USD
CY2017Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-34000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	62000	USD
CY2016Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1577000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4387000	USD
CY2017Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2593000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8708000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	157000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1096000	USD
	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	0	USD
	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	520000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	41739000	USD
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	1205000	USD
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	3271000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	183000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1034000	USD
CY2016Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	54000	USD
CY2017Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	155000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	479000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	6435000	USD
CY2017Q3	us-gaap	Liabilities Liabilities	52579000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	93990000	USD
CY2017Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	110415000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6435000	USD
CY2017Q3	us-gaap	Liabilities Current LiabilitiesCurrent	52247000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	107159000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	492000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	4997000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	11071000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-20292000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	18021000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-7084000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-25929000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-4825000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-33905000	USD
CY2016Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7377000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-26487000	USD
CY2017Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4825000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-33905000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	0	USD
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	185000	USD
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	7138000	USD
	us-gaap	Operating Expenses OperatingExpenses	21269000	USD
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	13761000	USD
	us-gaap	Operating Expenses OperatingExpenses	43165000	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-7138000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-21269000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4980000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-34384000	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	13159000	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	2059000	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	2000000	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	1941000	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	1667000	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	5228000	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	264000	USD
CY2016Q4	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	5272000	USD
CY2017Q3	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	8241000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	120000	USD
CY2017Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	57000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	34000	USD
CY2017Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0	USD
CY2016Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	1000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	5000	USD
CY2017Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	24000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	21000	USD
CY2016Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	75000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	73000	USD
CY2017Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	73000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	324000	USD
CY2016Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-34000	USD
CY2017Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	297000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	6396000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	28154000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	295000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	610000	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2017Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2017Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3394000	USD
CY2017Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2703000	USD
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	84508000	USD
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	22508000	USD
	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	0	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	11688000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	39835000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	143000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	789000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	562000	USD
CY2017Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	945000	USD
CY2016Q4	us-gaap	Receivables Long Term Contracts Or Programs ReceivablesLongTermContractsOrPrograms	0	USD
CY2017Q3	us-gaap	Receivables Long Term Contracts Or Programs ReceivablesLongTermContractsOrPrograms	520000	USD
CY2017Q3	us-gaap	Receivables Long Term Contracts Or Programs ReceivablesLongTermContractsOrPrograms	500000	USD
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5561000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16882000	USD
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11168000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	34457000	USD
CY2016Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	10000	USD
CY2016Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	10000	USD
CY2017Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	10000	USD
CY2016Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	0	USD
CY2016Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	0	USD
CY2017Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	450000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-64593000	USD
CY2017Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-98500000	USD
CY2017Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-98498000	USD
CY2016Q3	us-gaap	Revenues Revenues	0	USD
	us-gaap	Revenues Revenues	0	USD
CY2017Q3	us-gaap	Revenues Revenues	8781000	USD
	us-gaap	Revenues Revenues	8781000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	610000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	3052000	USD
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.628
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.621
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0138
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0200
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.11
CY2017Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y29D
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	87555000	USD
CY2017Q3	us-gaap	Stockholders Equity StockholdersEquity	57836000	USD
CY2016Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.0689655
CY2016Q3	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	293000	USD
	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	558000	USD
CY2017Q3	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	0	USD
	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	0	USD
CY2016Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	8483189	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	3071456	shares
CY2017Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	16911575	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	16851672	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Credit Risk</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents and available-for-sale securities. Substantially all of the Company’s cash is held by two financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. The primary focus of the Company’s investment strategy is to preserve capital and to meet liquidity requirements. The Company’s cash equivalents and available-for-sale securities are managed by external managers within the guidelines of the Company’s investment policy. The Company’s investment policy addresses the level of credit exposure by limiting concentration in any one corporate issuer and establishing a minimum allowable credit rating. To manage its credit risk exposure, the Company maintains its portfolio of cash equivalents and available-for-sale securities in fixed income securities denominated and payable in U.S. dollars. Permissible investments of fixed income securities include obligations of the U.S. government and its agencies, money market instruments including commercial paper and negotiable certificates of deposit, and highly rated corporate debt obligations and money market funds. The Company has not experienced any material credit losses on its investments. </font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates its estimates related to revenue recognition, accruals for research and development activities, stock-based compensation, and income taxes. Estimates related to revenue recognition include actual costs incurred versus total estimated budgeted cost of the Company's deliverables, actual costs incurred versus total estimated budgeted cost of variable consideration, and application of constraint in the determination of transaction price under its license and collaboration agreement with Janssen Biotech, Inc. (the "Janssen License and Collaboration Agreement"). Management bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to forecasted amounts and future events. Actual results may differ significantly from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001377121-17-000007-index-headers.html	Edgar Link	pending
0001377121-17-000007-index.html	Edgar Link	pending
0001377121-17-000007.txt	Edgar Link	pending
0001377121-17-000007-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
ptgx-20170930.xml	Edgar Link	completed
ptgx-20170930.xsd	Edgar Link	pending
ptgx-20170930_cal.xml	Edgar Link	unprocessable
ptgx-20170930_def.xml	Edgar Link	unprocessable
ptgx-20170930_lab.xml	Edgar Link	unprocessable
ptgx-20170930_pre.xml	Edgar Link	unprocessable
ptgx10-qq32017.htm	Edgar Link	pending
ptgx10-qq3ex311.htm	Edgar Link	pending
ptgx10-qq3ex312.htm	Edgar Link	pending
ptgx10-qq3ex321.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PTGX
Protagonist Therapeutics, Inc Stock $ptgx

2017 Q4 Form 10-Q Financial Statement

#000137712117000007 Filed on November 07, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PTGX Protagonist Therapeutics, Inc Stock $ptgx

2017 Q4 Form 10-Q Financial Statement

#000137712117000007 Filed on November 07, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PTGX
Protagonist Therapeutics, Inc Stock $ptgx